CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
Nutrof Total +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01269697
NCT01269697Phase 3Completed
CompareCT.gov

Lutein Influence on Macula of Persons Issued From Amd Parents

University Hospital, Bordeaux·interventional·Posted Jan 4, 2011·Updated May 20, 2013

In Brief

A Phase 3 clinical trial evaluating Nutrof Total and Placebo Nutrof total for Persons Issued From Amd Parents. Completed, enrolled 120 participants across 2 sites.

Detailed Summary

Age-related macular degeneration (AMD) is a degenerative disease of the centre of the retina (named macula) and is the leading cause of blindness in industrialized countries. There is growing interest in the potential preventive role of two carotenoids (lutein and zeaxanthin) of dietary origin, which specifically accumulate in the macula, where they form the macular pigment. A first step towards the demonstration of a preventive effect of macular pigment for AMD consists in the evaluation of the effect of lutein and zeaxanthin supplementation on their plasma and retinal concentrations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPersons Issued From Amd Parents
CountriesFrance
CollaboratorsLaboratoires Thea

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2011
Enrollment StartJan 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.5 years ago

Interventions

Nutrof Totaldietary

2 capsules 2 times per day during 6 month

Placebo Nutrof totaldietary

2 capsules 2 times per day during 6 month